Rezultati pretrage - Jianqin Shan

Detaljiziraj rezultate
  1. 1
    Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

    Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia od Ahmed Aribi, Gautam Borthakur, Farhad Ravandi, Jianqin Shan, Jan Davisson, Jorge E. Cortés, Hagop M. Kantarjian

    Izdano 2007
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response

    Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response od Hagop M. Kantarjian, Jianqin Shan, Daniel M. Jones, Susan O’Brien, Mary Beth Rios, Elias Jabbour, Jorge E. Cortés

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

    Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy od Dushyant Verma, Hagop M. Kantarjian, Jianqin Shan, Susan O’Brien, Zeev Estrov, Guillermo Garcia‐Manero, Charles Koller, Gautam Borthakur, Jorge E. Cortés

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

    Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response? od Elias Jabbour, Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan, Alfonso Quintás‐Cardama, Guillermo Garcia‐Manero, Mary Beth Rios, Jorge E. Cortés

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase

    Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chr... od Elias Jabbour, Hagop M. Kantarjian, Lynne V. Abruzzo, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Jianqin Shan, Mary Beth Rios, Jorge E. Cortés

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

    Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase recei... od Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah A. Thomas, Steven M. Kornblau, Susan O’Brien, Jorge E. Cortés

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

    Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia od Jorge E. Cortés, Dan Jones, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Charles Koller, Gautam Borthakur, Brenda Walker, Weiqiang Zhao, Jianqin Shan, Hagop M. Kantarjian

    Izdano 2009
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

    Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase od Yesid Alvarado, Hagop M. Kantarjian, Susan O’Brien, Stefan Faderl, Gautam Borthakur, Jan A. Burger, William G. Wierda, Guillermo Garcia‐Manero, Jianqin Shan, Jorge E. Cortés

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

    Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia od Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan, Xuelin Huang, Guillermo Garcia‐Manero, Stefan Faderl, Farhad Ravandi‐Kashani, Srđan Verstovšek, Mary Beth Rios, Jorge E. Cortés

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

    Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome od Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan, Ahmed Aribi, Guillermo Garcia‐Manero, Elias Jabbour, Farhad Ravandi, Jorge E. Cortés, Jan Davisson, Jean–Pierre J. Issa

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

    Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome od Hagop M. Kantarjian, Miloslav Beran, Jorge E. Cortés, Susan O’Brien, Francis J. Giles, Sherry Pierce, Jianqin Shan, William Plunkett, Michael J. Keating, Elihu H. Estey

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model

    Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model od Kiran Naqvi, Guillermo Garcia‐Manero, Sagar Sardesai, Jeong Hoon Oh, Carlos E. Vigil, Sherry Pierce, Xiudong Lei, Jianqin Shan, Hagop M. Kantarjian, María E. Suärez-Almazor

    Izdano 2011
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase od Jorge E. Cortés, Dan Jones, Susan O’Brien, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan M. Kadia, Gautam Borthakur, Denise Stigliano, Jianqin Shan, Hagop M. Kantarjian

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

    Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia od Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah A. Thomas, Jianqin Shan, Mary Beth Rios, Jorge E. Cortés

    Izdano 2002
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure

    Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure od Hagop M. Kantarjian, Susan O’Brien, Moshe Talpaz, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srđan Verstovšek, Mary Beth Rios, Jianqin Shan, Francis J. Giles, Jorge E. Cortés

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

    Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities od Farhad Ravandi, Jean–Pierre J. Issa, Guillermo Garcia‐Manero, Susan O’Brien, Sherry Pierce, Jianqin Shan, Gautam Borthakur, Srđan Verstovšek, Stefan Faderl, Jorge E. Cortés, Hagop M. Kantarjian

    Izdano 2009
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome

    Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome od Hagop M. Kantarjian, Susan O’Brien, Xuelin Huang, Guillermo Garcia‐Manero, Farhad Ravandi, Jorge E. Cortés, Jianqin Shan, Jan Davisson, Carlos E. Bueso‐Ramos, Jean–Pierre J. Issa

    Izdano 2007
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

    Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: od Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Francis J. Giles, Stefan Faderl, Elias Jabbour, Guillermo Garcia‐Manero, William G. Wierda, Sherry Pierce, Jianqin Shan, Elihu H. Estey

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

    Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia od Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Daniel M. Jones, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jorge E. Cortés

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

    Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy od Farhad Ravandi, Jorge E. Cortés, Stefan Faderl, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Fabio P S Santos, Jianqin Shan, Mark Brandt, Marcos de Lima, Sherry Pierce, Hagop M. Kantarjian

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: